Solithromycin is a ketolide antibiotic undergoing clinical development for the treatment of community-acquired pneumonia (CAP) and other infections.
Investigated for the treatment of community-acquired pneumonia (CAP).
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.